We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Oncologic PET Registry Data Confirm FDG-PET has Major Impact on Management of Cancer Patient Care

By MedImaging staff writers
Posted on 21 Apr 2008
A new study analyzed data regarding nearly 23,000 patients contributed to a U.S. More...
oncologic PET registry by more than 1200 facilities in the United States providing positron emission tomography (PET) scans.

Clinicians changed the intended care of more than one in three cancer patients as the result of fluorodeoxyglucose- (FDG)-PET scan findings, according to a study of data from the U.S. National Oncologic PET Registry (NOPR), published online March 24, 2008, in the Journal of Clinical Oncology (JCO).

Sponsored by the Academy of Molecular Imaging (AMI; Los Angeles, CA, USA) and managed by the American College of Radiology (ACR; Philadelphia, PA, USA) and American College of Radiology Imaging Network (ACRIN), the NOPR was designed to collect questionnaire data from referring physicians on intended patient management before and after an FDG-PET scan.

The NOPR-participating PET facility collected from referring physicians both a pre-PET questionnaire (documenting study indication, cancer type and anticipated stage, and planned management if PET were not available) and one of several post-PET questionnaires that assessed the referring physician's planned management in light of the FDG-PET findings.

Analysis of data collected found that FDG-PET is associated with a 36.5% change in the decision of whether or how to treat a patient's cancer. NOPR working group co-chair R. Edward Coleman, M.D., professor of radiology and chief of the division of nuclear medicine at Duke University School of Medicine (Durham, NC, USA) and an AMI founding member, commented, "We were especially surprised by the impact of the PET findings on patients who were originally planned to have a biopsy. The procedure was avoided in approximately three-quarters of these patients.”

FDG-PET, is an imaging modality that images the function of cells to show differences between healthy tissue and diseased tissue. It uses a small amount of a radioactive chemical, which is combined with glucose. This combination is called FDG, and is used to evaluate various neurologic and cardiac disorders, as well as for diagnosing, staging, and monitoring the treatment of many different cancers.


Related Links:
National Oncologic PET Registry
Virginia Commonwealth University
American College of Radiology Imaging Network

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.